MDWerks, Inc. (MDWK): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
MDWerks, Inc. (MDWK) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 MDWERKS, INC. Independent Director Agreement Jeff Hopmayer Dated as of June 26, 2026 This Independent Director Agreement (this “Agreement”), dated and made effective as of the date first set forth above (the “Effective Date”), is entered
- Person
- Jeff Hopmayer
- Title
- Board of Directors
- Action
- appointed
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
This is primarily governance and committee-structure information. Without disclosed compensation figures, equity awards, or operational updates in the provided excerpt, the direct trading impact is likely small.
Market read
The filing updates board composition and committee leadership, which may matter for longer-term strategy but does not provide new financial or deal catalysts in the excerpt.
What to watch
Traders may want to check whether the agreement includes specific compensation amounts or equity grants in sections not shown here, which could affect near-term expectations.
Background
The document is an SEC Form 8-K (Item 5.02) with an exhibit containing an independent director agreement for Jeff Hopmayer, dated June 26, 2026.
Ticker impact
MDWerks filed an 8-K for Item 5.02, appointing Jeff Hopmayer as an independent director and Head of the Technology Commercialization Committee.
Likely limited near-term impact; any move would be sentiment-driven rather than fundamentals.
The filing describes governance and committee service terms (independent director agreement, term length, and definitions like Cause/Good Reason) without new operating metrics, contracts, or capital actions.
Market effects
Minimal, as this is company-specific governance documentation rather than sector-wide regulatory or operational change.
None indicated.
None indicated.
Counterpoint
The appointment could signal a strategic push on technology commercialization, but the filing text provided does not include measurable milestones or funding changes.
Key entities
- issuerMDWerks, Inc.
Company filing the 8-K and entering into an independent director agreement.
- directorJeff Hopmayer
Appointed independent director and Head of the Technology Commercialization Committee under the agreement.

